"S\u00E9rov\u00E1 hladina cystatinu C pro lep\u0161\u00ED posouzen\u00ED glomerul\u00E1rn\u00ED filtrace u pacient\u016F s cystickou fibr\u00F3zou l\u00E9\u010Den\u00FDch amikacinem" . . . . "4" . "Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikac"@en . "SOUHRN \u00DAvod a c\u00EDl: Sledov\u00E1n\u00ED funkce ledvin u pacient\u016F s cystickou fibr\u00F3zou (CF) je nezbytn\u00E9. D\u00E1vkovac\u00ED re\u017Eim amikacinu je pravideln\u011B upravov\u00E1n v z\u00E1vislosti na glomerul\u00E1rn\u00ED filtraci (GF) pacienta. C\u00EDlem studie bylo posoudit vyu\u017Eit\u00ED cystatinu C (CyC) pro monitorov\u00E1n\u00ED l\u00E9\u010Dby amikacinem spolu s dal\u0161\u00EDmi markery tubul\u00E1rn\u00ED a glomerul\u00E1rn\u00ED funkce a po\u0161kozen\u00ED ledvin [N-acetyl - D glucosaminidase (NAG), kreatinin a clearance kreatininu ]. Metodika: Srovn\u00E1vali jsme GF odhadnutou ze s\u00E9rov\u00E9 koncentrace kreatininu (Cockcroft-Gault vzorec) a CyC (vzorec dle Grubba). Sedmdes\u00E1t jedna pacient\u016F (pr\u016Fm\u011Brn\u00FD v\u011Bk 12 let, rozp\u011Bt\u00ED 4-28 let) s CF bylo l\u00E9\u010Deno intermitentn\u00ED intraven\u00F3zn\u00ED infuz\u00ED amikacinu. Tubul\u00E1rn\u00ED nefrotoxicita byla vy\u0161et\u0159ov\u00E1na pomoc\u00ED m\u011B\u0159en\u00ED NAG v mo\u010Di/ kreatinin v mo\u010Di (U-NAG / U-kreatinin). Koncentrace v\u0161ech marker\u016F byly m\u011B\u0159eny p\u0159ed zah\u00E1jen\u00EDm l\u00E9\u010Dby amikacinem a 3, 5, 7, 10 a 12 den l\u00E9\u010Dby. Fluorescen\u010Dn\u00ED polariza\u010Dn\u00ED anal\u00FDza, turbidimetrie, kreatinin enzymatick\u00E1 fotometrick\u00E1 metoda a fluorimetrie byly pou\u017Eity pro stanoven\u00ED s\u00E9rov\u00E9ho amikacinu, CyC, kreatininu a aktivity NAG v mo\u010Di. Pomoc\u00ED receiver operating characteristic (ROC) anal\u00FDzy jsme posoudili vliv GF odhadnut\u00E9 ze s\u00E9rov\u00E9ho kreatininu a s\u00E9rov\u00E9ho CyC na predikci clearance amikacinu b\u011Bhem l\u00E9\u010Dby aminoglykosidy. V\u00FDsledky: V\u00FDznamn\u00E9 rozd\u00EDly v pom\u011Bru U-NAG / U-kreatinin byly zji\u0161t\u011Bny p\u0159ed a po l\u00E9\u010Db\u011B amikacinem (p <0,001). Hladina s\u00E9rov\u00E9ho kreatininu a clearance kreatininu na konci pod\u00E1v\u00E1n\u00ED amikacinu (12. den) neprok\u00E1zaly \u017E\u00E1dn\u00E9 v\u00FDznamn\u00E9 rozd\u00EDly ve srovn\u00E1n\u00ED s hodnotami nam\u011B\u0159en\u00FDmi p\u0159ed zah\u00E1jen\u00EDm l\u00E9\u010Dby (0. den). 5., 7., 10. a 12. den bylo zaznamen\u00E1no v\u00FDznamn\u00E9 zv\u00FD\u0161en\u00ED s\u00E9rov\u00FDch hladin CyC (p <0,001) a CyC clearance uk\u00E1zala v\u00FDznamn\u00FD pokles (p <0,001) ve srovn\u00E1n\u00ED s hodnotami nam\u011B\u0159en\u00FDmi v den 0. Pom\u011Br clearance amikacinu / clearance kreatininu klesl b\u011Bhem l\u00E9\u010Dby zat\u00EDmco clearance amikacinu / CyC a clearance amikacinu / clearance CyC se zv\u00FD\u0161il. Z\u00E1v\u011Br: Uk\u00E1zali jsme, \u017Ee pom\u011Br U-NAG"@cs . "N" . "394488" . "Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikac"@en . . "SOUHRN \u00DAvod a c\u00EDl: Sledov\u00E1n\u00ED funkce ledvin u pacient\u016F s cystickou fibr\u00F3zou (CF) je nezbytn\u00E9. D\u00E1vkovac\u00ED re\u017Eim amikacinu je pravideln\u011B upravov\u00E1n v z\u00E1vislosti na glomerul\u00E1rn\u00ED filtraci (GF) pacienta. C\u00EDlem studie bylo posoudit vyu\u017Eit\u00ED cystatinu C (CyC) pro monitorov\u00E1n\u00ED l\u00E9\u010Dby amikacinem spolu s dal\u0161\u00EDmi markery tubul\u00E1rn\u00ED a glomerul\u00E1rn\u00ED funkce a po\u0161kozen\u00ED ledvin [N-acetyl - D glucosaminidase (NAG), kreatinin a clearance kreatininu ]. Metodika: Srovn\u00E1vali jsme GF odhadnutou ze s\u00E9rov\u00E9 koncentrace kreatininu (Cockcroft-Gault vzorec) a CyC (vzorec dle Grubba). Sedmdes\u00E1t jedna pacient\u016F (pr\u016Fm\u011Brn\u00FD v\u011Bk 12 let, rozp\u011Bt\u00ED 4-28 let) s CF bylo l\u00E9\u010Deno intermitentn\u00ED intraven\u00F3zn\u00ED infuz\u00ED amikacinu. Tubul\u00E1rn\u00ED nefrotoxicita byla vy\u0161et\u0159ov\u00E1na pomoc\u00ED m\u011B\u0159en\u00ED NAG v mo\u010Di/ kreatinin v mo\u010Di (U-NAG / U-kreatinin). Koncentrace v\u0161ech marker\u016F byly m\u011B\u0159eny p\u0159ed zah\u00E1jen\u00EDm l\u00E9\u010Dby amikacinem a 3, 5, 7, 10 a 12 den l\u00E9\u010Dby. Fluorescen\u010Dn\u00ED polariza\u010Dn\u00ED anal\u00FDza, turbidimetrie, kreatinin enzymatick\u00E1 fotometrick\u00E1 metoda a fluorimetrie byly pou\u017Eity pro stanoven\u00ED s\u00E9rov\u00E9ho amikacinu, CyC, kreatininu a aktivity NAG v mo\u010Di. Pomoc\u00ED receiver operating characteristic (ROC) anal\u00FDzy jsme posoudili vliv GF odhadnut\u00E9 ze s\u00E9rov\u00E9ho kreatininu a s\u00E9rov\u00E9ho CyC na predikci clearance amikacinu b\u011Bhem l\u00E9\u010Dby aminoglykosidy. V\u00FDsledky: V\u00FDznamn\u00E9 rozd\u00EDly v pom\u011Bru U-NAG / U-kreatinin byly zji\u0161t\u011Bny p\u0159ed a po l\u00E9\u010Db\u011B amikacinem (p <0,001). Hladina s\u00E9rov\u00E9ho kreatininu a clearance kreatininu na konci pod\u00E1v\u00E1n\u00ED amikacinu (12. den) neprok\u00E1zaly \u017E\u00E1dn\u00E9 v\u00FDznamn\u00E9 rozd\u00EDly ve srovn\u00E1n\u00ED s hodnotami nam\u011B\u0159en\u00FDmi p\u0159ed zah\u00E1jen\u00EDm l\u00E9\u010Dby (0. den). 5., 7., 10. a 12. den bylo zaznamen\u00E1no v\u00FDznamn\u00E9 zv\u00FD\u0161en\u00ED s\u00E9rov\u00FDch hladin CyC (p <0,001) a CyC clearance uk\u00E1zala v\u00FDznamn\u00FD pokles (p <0,001) ve srovn\u00E1n\u00ED s hodnotami nam\u011B\u0159en\u00FDmi v den 0. Pom\u011Br clearance amikacinu / clearance kreatininu klesl b\u011Bhem l\u00E9\u010Dby zat\u00EDmco clearance amikacinu / CyC a clearance amikacinu / clearance CyC se zv\u00FD\u0161il. Z\u00E1v\u011Br: Uk\u00E1zali jsme, \u017Ee pom\u011Br U-NAG" . "Journal of Clinical Pharmacy and Therapeutics" . . . "Tich\u00E1, Jana" . "S\u00E9rov\u00E1 hladina cystatinu C pro lep\u0161\u00ED posouzen\u00ED glomerul\u00E1rn\u00ED filtrace u pacient\u016F s cystickou fibr\u00F3zou l\u00E9\u010Den\u00FDch amikacinem"@cs . . "7"^^ . "amikacin clearance, creatinine, cystatin C, cystic fibrosis, glomerular filtrati"@en . "33" . "9"^^ . "RIV/00023884:_____/08:#0002662" . . "S\u00E9rov\u00E1 hladina cystatinu C pro lep\u0161\u00ED posouzen\u00ED glomerul\u00E1rn\u00ED filtrace u pacient\u016F s cystickou fibr\u00F3zou l\u00E9\u010Den\u00FDch amikacinem"@cs . "SUMMARY Background and objective: Monitoring of renal function in cystic fibrosis (CF) patients is essential. The dosage regimen of amikacin is regularly modified according to the patient s glomerular filtration rate (GFR). The aim of the study was to evaluate the use of cystatin C (CyC) for monitoring amikacin therapy along with other markers of renal tubular and glomerular function, and damage [N-acetyl--D glucosaminidase (NAG), creatinine level and creatinine clearance]. Methods: We compared the GFR, estimated from the serum concentrations of creatinine (Cockcroft Gault formula) and CyC (Grubb s formula). Seventy-one patients (mean age 12 years; range 4 28 years) with CF were treated by intermittent intravenous infusion of amikacin. Tubular nephrotoxicity was investigated by measurement of urine NAG /urine creatinine ratio (U-NAG / U-creatinine). Concentrations of all markers were measured before starting amikacin therapy and at days 3, 5, 7, 10 and 12. Fluorescence polarization analysis, turbidimetry, enzymatic phototometric creatinine deaminase method and fluorimetry were used for determination of serum amikacin, serum CyC, creatinine and urine NAG aktivity.Receiver operating characteristic (ROC) analysis was performed to assess the influence of GFR estimated from serum creatinine and serum CyC for the prediction of amikacin clearance during aminoglycoside therapy. Results: Significant differences in the rate of U-NAG /U-creatinine were noted before and after treatment with amikacin (P <0.001). Serum creatinine levels and creatinine clearance at the end of amikacin therapy (12th day) did not show any significant differences in comparison with the levels measured before the start of therapy (0th day). At days 5, 7, 10 and 12, serum CyC levels showed a significant elevation (P <0.001), and CyC clearance showed a significant decrease (P <0.001) in comparison with the levels measured at day 0. The ratio of amika"@en . "RIV/00023884:_____/08:#0002662!RIV12-MZ0-00023884" . . "S\u00E9rov\u00E1 hladina cystatinu C pro lep\u0161\u00ED posouzen\u00ED glomerul\u00E1rn\u00ED filtrace u pacient\u016F s cystickou fibr\u00F3zou l\u00E9\u010Den\u00FDch amikacinem" . "0269-4727" . "1"^^ . . "[F50E75A703D1]" . . . . . . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . .